3073 Exploratory Analysis of Frontline Therapies in REVEL: A Randomized Phase III Study of Ramucirumab (RAM) Plus Docetaxel (DOC) Versus DOC for the Treatment of Stage IV Non-Small-cell Lung Cancer (NSCLC) after Disease Progression on Platinum-Based Therapy
European journal of cancer(2015)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined